Glaukos Corp (USD)
GKOS
Overview
Key Information
Legal Documents
Financials

Overview

SectorHealthcare
Industry-
Day Range53.72 | 57.69
52-Wk Range50.60 | 84.65
Last Close56.99
Mkt Cap (m)2,468.97
Dividend yield-
ISINUS3773221029
Volume471,474
Exchange VenueNYS

Company Profile

Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma.

Key Information
Price/Earning-
Price/Book12.99
Price/Sales9.21
P/CF98.99
Rev Growth (3 year avg)36.23
EPS Growth (3 year avg)-
Operating Margin % -7.17
Net Margin %-7.14
Return on Equity-8.30
Debt/Equity-

Legal Documents

Prospectus
en 17/10/2019
Annual Report
en 31/12/2018

Financials

Income Statement
USD201320142015201620172018
Revenue (m)214672114159181
Operating Income (m)-14-13-104-2-13
Net Income (m)-13-12-375-13
Basic EPS-0.51-0.51-2.130.140.00-0.37
Avg. Diluted Shares Outstanding (m)252417363435
Balance Sheet
USD201320142015201620172018
Current Assets (m)1211104120149177
Non Current Assets (m)191513141630
Total Assets (m)3126117134166207
Current Liabilities (m)52020172730
Total Liabilities (m)------
Total Equity (m)-141-15195117138174
Cash Flows
USD201320142015201620172018
Operating Cash Flows (m)-13-7-2122619
Capital Expenditure (m)-1-1-1-6-6-10
Figures are quoted in USD unless stated otherwise
0.00 (0.00%)
$
56.99
Last Price